BIT Stock Overview
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Biotron Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.057 |
52 Week High | AU$0.13 |
52 Week Low | AU$0.024 |
Beta | -0.52 |
1 Month Change | -19.72% |
3 Month Change | -38.04% |
1 Year Change | 103.57% |
3 Year Change | 11.76% |
5 Year Change | -25.00% |
Change since IPO | -33.32% |
Recent News & Updates
Recent updates
Shareholder Returns
BIT | AU Biotechs | AU Market | |
---|---|---|---|
7D | 5.6% | 3.3% | 2.0% |
1Y | 103.6% | -4.6% | 9.5% |
Return vs Industry: BIT exceeded the Australian Biotechs industry which returned -4.6% over the past year.
Return vs Market: BIT exceeded the Australian Market which returned 9.5% over the past year.
Price Volatility
BIT volatility | |
---|---|
BIT Average Weekly Movement | 11.3% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.4% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: BIT's share price has been volatile over the past 3 months.
Volatility Over Time: BIT's weekly volatility (11%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | n/a | Michelle Miller | www.biotron.com.au |
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited Fundamentals Summary
BIT fundamental statistics | |
---|---|
Market cap | AU$51.43m |
Earnings (TTM) | -AU$4.02m |
Revenue (TTM) | AU$1.65m |
30.2x
P/S Ratio-12.3x
P/E RatioIs BIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIT income statement (TTM) | |
---|---|
Revenue | AU$1.65m |
Cost of Revenue | AU$0 |
Gross Profit | AU$1.65m |
Other Expenses | AU$5.67m |
Earnings | -AU$4.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0045 |
Gross Margin | 100.00% |
Net Profit Margin | -244.54% |
Debt/Equity Ratio | 0% |
How did BIT perform over the long term?
See historical performance and comparison